News

Drug Discovery World | Are scalable data science platforms the way forward?

Marilyn Matz, CEO of Paradigm4, and Zachary Pitluk, Vice President of Life Sciences at Paradigm4, explain why scalable data science platforms are key to supporting integrated analysis of single-cell genomic data sets.

whitepages icon x

Pharma’s Almanac | What do you think most differentiates the U.S. pharma/biopharma industry or the market?

Paradigm4’s Marilyn Matz reflects on the understanding complex biological phenomena has required concurrent advances in experimental methods and computing power.

whitepages icon x

Pharma’s Almanac || What do you consider the biggest challenge that the pharma/biopharma industry currently faces?

Marilyn Matz, Chief Executive Officer and Co-Founder, Paradigm4 “Genomics’ role in the life science vision “is only as credible as its implementation,”

whitepages icon x

Manufacturing Chemist | Multidimensional data analysis platforms: meeting new FDA calls for consistent evidence from CGT developers

Recent news that the US Food and Drug Administration (FDA) will ask cell and gene therapy (CGT) developers to provide more consistent evidence with their submissions has resulted in drug makers delaying development plans — and working on new ways to address the agency’s concerns